A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

To be considered for this study, you would generally need to be between 40 and 75 years old and have a confirmed diagnosis of Multiple System Atrophy (MSA), either the Parkinsonian type (MSA-P) or the Cerebellar type (MSA-C). Your MSA symptoms should have started within the last five years, and your doctor should believe you are likely to live for at least another three years.

There are also some reasons why you might not be able to join. For example, if you've previously taken this specific study medicine (Amlenetug), or if you're taking another experimental treatment. Also, if you have other serious medical conditions that might affect your brain or nervous system, or a family history of MSA in several close relatives, you might not be able to take part. Researchers also check for other movement disorders that could be mistaken for MSA.

If you join this study, it will involve several stages. First, there's a screening period lasting between 10 days and up to 6 weeks to ensure you meet all the requirements. After that, there's a main treatment period of 72 weeks where you'll receive either Amlenetug or a placebo. You won't know which one you're getting during this time.

During both the main treatment period and an optional extended period, you will receive the study medicine as an infusion directly into a vein. These infusions will happen approximately every four weeks. If you choose to continue into the optional extended treatment period, which also lasts 72 weeks, everyone will receive Amlenetug during this phase. Throughout the study, you'll have regular visits where doctors will monitor your health, check your symptoms, and take blood samples to see how you're responding to the treatment.